Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS G12C
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
KRAS overexpression (2)
KRAS G13D overexpression (1)
KRAS expression (0)
KRAS overexpression (2)
KRAS G13D overexpression (1)
KRAS expression (0)
›
Related tests:
Guardant360® CDx (54)
therascreen® KRAS RGQ PCR Kit (5)
Resolution ctDx FIRST Assay (1)
Guardant360® CDx (54)
therascreen® KRAS RGQ PCR Kit (5)
Resolution ctDx FIRST Assay (1)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib
Sensitive: A1 - Approval
sotorasib
Sensitive
:
A1
sotorasib
Sensitive: A1 - Approval
sotorasib
Sensitive
:
A1
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
adagrasib
Sensitive: A1 - Approval
adagrasib
Sensitive
:
A1
adagrasib
Sensitive: A1 - Approval
adagrasib
Sensitive
:
A1
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
adagrasib
Sensitive: A1 - Approval
adagrasib
Sensitive
:
A1
adagrasib
Sensitive: A1 - Approval
adagrasib
Sensitive
:
A1
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
cetuximab + adagrasib
Sensitive: A1 - Approval
cetuximab + adagrasib
Sensitive
:
A1
cetuximab + adagrasib
Sensitive: A1 - Approval
cetuximab + adagrasib
Sensitive
:
A1
KRAS G12C
Colorectal Cancer
KRAS G12C
Colorectal Cancer
panitumumab + sotorasib
Sensitive: A1 - Approval
panitumumab + sotorasib
Sensitive
:
A1
panitumumab + sotorasib
Sensitive: A1 - Approval
panitumumab + sotorasib
Sensitive
:
A1
KRAS G12C
Ampulla of Vater Carcinoma
KRAS G12C
Ampulla of Vater Carcinoma
sotorasib
Sensitive: A2 - Guideline
sotorasib
Sensitive
:
A2
sotorasib
Sensitive: A2 - Guideline
sotorasib
Sensitive
:
A2
KRAS G12C
Pancreatic Adenocarcinoma
KRAS G12C
Pancreatic Adenocarcinoma
sotorasib
Sensitive: A2 - Guideline
sotorasib
Sensitive
:
A2
sotorasib
Sensitive: A2 - Guideline
sotorasib
Sensitive
:
A2
KRAS G12C
Pancreatic Adenocarcinoma
KRAS G12C
Pancreatic Adenocarcinoma
adagrasib
Sensitive: A2 - Guideline
adagrasib
Sensitive
:
A2
adagrasib
Sensitive: A2 - Guideline
adagrasib
Sensitive
:
A2
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
panitumumab + sotorasib
Sensitive: A2 - Guideline
panitumumab + sotorasib
Sensitive
:
A2
panitumumab + sotorasib
Sensitive: A2 - Guideline
panitumumab + sotorasib
Sensitive
:
A2
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
cetuximab + sotorasib
Sensitive: A2 - Guideline
cetuximab + sotorasib
Sensitive
:
A2
cetuximab + sotorasib
Sensitive: A2 - Guideline
cetuximab + sotorasib
Sensitive
:
A2
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
panitumumab + adagrasib
Sensitive: A2 - Guideline
panitumumab + adagrasib
Sensitive
:
A2
panitumumab + adagrasib
Sensitive: A2 - Guideline
panitumumab + adagrasib
Sensitive
:
A2
KRAS G12C
Rectal Cancer
KRAS G12C
Rectal Cancer
cetuximab + adagrasib
Sensitive: A2 - Guideline
cetuximab + adagrasib
Sensitive
:
A2
cetuximab + adagrasib
Sensitive: A2 - Guideline
cetuximab + adagrasib
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.